Interv Akut Kardiol. 2004;3(3):142

WATCH: warfarin a protidestičková léčba u chronického srdečního selhání

Jiří Vítovec
I. interní kardioangiologická klinika FN u sv. Anny v Brně

Keywords: clopidogrel, aspirin, warfarin, chronic heart failure.

Published: December 31, 2004  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vítovec J. WATCH: warfarin a protidestičková léčba u chronického srdečního selhání. Interv Akut Kardiol. 2004;3(3):142.

Výsledky největší studie s antitrombotickou léčbou u srdečního selhání WATCH, neukázaly signifikantní rozdíl mezi kyselinou acetylosalycilovou (ASA), warfarinem nebo clopidogrelem v složeném primárním cíli (celkové úmrtnost, nefatální infarkt myokardu - IM a nefatální cévní mozková příhoda - CMP). Ale ve studii se ukázal významný rozdíl v hospitalizacích pro srdeční selhání ve prospěch warfarinu ve srovnání s ASA.

WATCH: WARFARIN AND ANTIPLATELET THERAPY IN CHRONIC HEART FAILURE TRIAL

The results of the Warfarin and Antiplatelet Therapy in Chronic Heart Failure Trial, the largest trial conducted to date of antithrombotic treatments in heart failure, failed to show significant differences between aspirin, warfarin, and clopidogrel in the primary composite endpoint of all-cause mortality, nonfatal myocardial infarction (MI), and nonfatal stroke. It did, however, reveal an "intriguing" lower rate of heart failure hospitalizations for warfarin vs aspirin.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article


    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.